Clinical Trials in Taipei, Neihu District
2 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 2
THIO Sequenced With Cemiplimab in Advanced NSCLC
Carcinoma, Non-Small Cell Lung
Maia Biotechnology227 enrolled33 locationsNCT05208944
Recruiting
Phase 2
To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
OBI Pharma, Inc60 enrolled7 locationsNCT05442060